Halbrook CJ, Lyssiotis CA, di Magliano MP, et al. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer. Lancet. 2020;39:2008–20.

Article  Google Scholar 

Yu J, Ploner A, Kordes M, et al. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinom. Int J Cancer. 2021;148:2048–58.

Article  CAS  PubMed  Google Scholar 

Fahrmann JF, Schmidt CM, Mao X, et al. Lead-time trajectory of CA 19–9 as an anchor marker for pancreatic cancer early detection. Gastroenterology. 2021;160(4):1373–83.

Article  CAS  PubMed  Google Scholar 

Dbouk M, Abe T, Koi C, et al. Diagnostic Performance of a Tumor marker gene test to personalize serum CA 19–9 reference ranges. Clin Cancer Res. 2023;29(20):4178–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin LK, Wei L, Trolli E, et al. Elevated baseline CA 19–9 levels correlate with adverse prognosis in patients with early-or advanced-stage pancreas cancer. Med Oncol. 2012;29:3101–7.

Article  CAS  PubMed  Google Scholar 

Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen 19–9 and Lewis antigens in pancreatic cancer. Can Res. 1987;47:5501–3.

CAS  Google Scholar 

Suhre K, McCarthy MI, Schwenk JM. Genetics meets proteomics: perspectives for large population-based studies. Nat Rev Genet. 2021;22:19–37.

Article  CAS  PubMed  Google Scholar 

Pietzner M, Wheeler E, Carrasco-Zanini J, et al. Mapping the proteo-genomic convergence of human diseases. Science. 2021;37:1–28.

Google Scholar 

Viode A, van Zalm P, Smolen KK, et al. A simple, time-and cost-effective, high-throughput depletion strategy for deep plasma proteomic. Sci Adv. 2023;9:9717–22.

Article  Google Scholar 

Boyd LNC, Ali M, Leeflang MMG, et al. Diagnostic accuracy and added value of blood-based protein biomarkers for pancreatic cancer: a meta-analysis of aggregate and individual participant dat. eClin Med. 2023;55:55–67.

Google Scholar 

Gerdtsson AS, Wingren C, Persson H, et al. Plasma protein profiling in a stage defined pancreatic cancer cohort–Implications for early diagnosis. Mol Oncol. 2016;10:1305–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma AK, Gupta K, Mishra A, et al. Non-invasive detection of pancreatic adenocarcinoma using Ga-68 labelled epha2 targeting peptide. Can Res. 2023;83:2768–2768.

Article  Google Scholar 

Larsson SC, Butterworth AS, Burgess S. Mendelian randomization for cardiovascular diseases: principles and applications. Eur Heart J. 2023;44:4913–24.

Article  PubMed  PubMed Central  Google Scholar 

Qian L, Zhu J, Xue Z, et al. Proteomic landscape of epithelial ovarian cancer. Nat Commun. 2024;15:6462–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith-Byrne K, Hedman Å, Dimitriou M, et al. Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancer. Nat Commun. 2024;15:3621–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhindsa RS, Burren OS, Sun BB, et al. Rare variant associations with plasma protein levels in the UK Biobank. Nature. 2023;622:339–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferkingstad E, Sulem P, Atlason BA, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53:1712–21.

Article  CAS  PubMed  Google Scholar 

Sun BB, Maranville JC, Peters JE, et al. Genomic atlas of the human plasma proteome. Nature. 2018;558:73–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun BB, Chiou J, Traylor M, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Folkersen L, Gustafsson S, Wang Q, et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab. 2020;2:1135–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yao C, Chen G, Song C, et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat Commun. 2018;9:3268–78.

Article  PubMed  PubMed Central  Google Scholar 

Yuan S, Xu F, Li X, et al. Plasma proteins and onset of type 2 diabetes and diabetic complications: Proteome-wide Mendelian randomization and colocalization analyse. Cell Rep Med. 2023;4:101174–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papadimitriou N, Dimou N, Tsilidis KK, et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat Commun. 2020;1:597–606.

Article  Google Scholar 

Gonçalves E, Poulos RC, Cai Z, et al. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell. 2022;4:835–49.

Article  Google Scholar 

Vasaikar S, Huang C, Wang X, et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell. 2019;177:1035–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun J, Zhao J, Jiang F, et al. Identification of novel protein biomarkers and drug targets for colorectal cancer by integrating human plasma proteome with genome. Genome Med. 2023;15:75–87.

Article  PubMed  PubMed Central  Google Scholar 

Mälarstig A, Grassmann F, Dahl L, et al. Evaluation of circulating plasma proteins in breast cancer using Mendelian randomisation. Nat Commun. 2023;14:7680–8.

Article  PubMed  PubMed Central  Google Scholar 

Zhu J, Shu X, Guo X, et al. Associations between genetically predicted blood protein biomarkers and pancreatic cancer risk. Cancer Epidemiol Biomark Prev. 2020;29:1501–8.

Article  CAS  Google Scholar 

Zhou S, Tao B, Guo Y, et al. Integrating plasma protein-centric multi-omics to identify potential therapeutic targets for pancreatic cancer. J Transl Med. 2024;22:557–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berens EB, Sharif GM, Schmidt MO, et al. Keratin-associated protein 5–5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene. 2017;36(5):593–605.

Article  CAS  PubMed  Google Scholar 

Du H, Wang X, Dong R, et al. miR-601 inhibits proliferation, migration and invasion of prostate cancer stem cells by targeting KRT5 to inactivate the Wnt signaling pathway. Int J Clin Exp Pathol. 2019;12(12):4361–79.

PubMed  PubMed Central  Google Scholar 

Zhao X, Sun Z, Li H, et al. MiR-135a-5p modulates biological functions of thyroid carcinoma cells via targeting VCAN 3′-UTR. Cancer Biomark. 2017;20(2):207–16.

Article  CAS  PubMed